Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Medicine 13, 129-131 (1 February 2007) | doi:10.1038/nm0207-129;
Seeing what Alzheimer saw
&
Abstract
Since Alois Alzheimer's seminal report in November of 1906, pathologists have regarded amyloid-β deposits in senile plaques and neurofibrillary tangles as essential for the diagnosis of Alzheimer disease. In the past 30 years, progress has been made in developing biomarkers to bridge the gap between the 'gold standard' of post-mortem neuropathological confirmation and the clinical diagnosis of Alzheimer disease based on the recognition of cognitive deficits and exclusion of other dementing disorders.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).